論文・技術情報追加のお知らせ

1. Heterogeneity in adverse events associated with lumateperone: a study on potential subgroup-specific differences.

Lumateperoneの副作用の異質性をサブグループ別にFAERSで解析。

対象DB：FAERS

2. Cutaneous Allodynia Associated With GLP-1RA Tirzepatide for Weight Management: A Case Series.

減量用Tirzepatide使用に伴う皮膚アロディニアの症例シリーズ。

対象DB：FAERS

3. Vaccine Adverse Effects: An Overview.

ワクチンの副作用に関する全体像の概要（オーバービュー）。

対象DB：FAERS,VAERS

4. Drug-induced eosinophilic pneumonia: a real-world data mining study of the FAERS and Vigibase database reveals potential safety signals and risk patterns.

薬剤性好酸球性肺炎をFAERSとVigiBaseのデータで解析。

対象DB：FAERS,VigiBase

5. Tecartus Real-World Adverse Event Reporting System in a Middle-Aged and Elderly Population: A FAERS-Based Pharmacovigilance Study.

中高年におけるTecartusの副作用報告をFAERSでリアルワールド解析。

対象DB：FAERS

6. Bleeding-Related Interactions Between DOACs and Cardiovascular Drugs: Insights from FDA adverse event reporting system.

DOACと心血管薬の出血関連相互作用をFAERSデータから特定。

対象DB：FAERS,KAERS

7. Pseudolymphoma Associated with Calcium Channel Blockers: A FAERS Disproportionality Analysis Comparing Dihydropyridines and Non-Dihydropyridines.

カルシウム拮抗薬による仮性リンパ腫リスクをFAERSで比較解析。

対象DB：FAERS

8. Janus Kinase Inhibitors and Cardiovascular Safety: Interpreting Signals from the Korea Adverse Event Reporting System.

韓国の副作用報告DBを用いたJAK阻害薬の心血管安全性の解析。

対象DB：FAERS,KAERS

9. Peripheral nervous system safety signals of antibody-drug conjugates: cross-database reproducibility and labeling gaps identified using FAERS, JADER, and CVARD.

ADC製剤の末梢神経系副作用の安全シグナルを複数DBで検証。

対象DB：CVAR,FAERS,JADER

10. Drug-drug interactions between sex hormones and analgesics linked to thromboembolic events: an FDA adverse event reporting system analysis.

性ホルモンと鎮痛薬の相互作用による血栓塞栓リスクの解析。

対象DB：FAERS

11. Similarity-based profiling of pharmacovigilance data for drug safety pattern discovery.

副作用DBの類似性プロファイリングによる安全性パターンの発見。

対象DB：FAERS,KAERS

12. Risk factors for drug-related gestational diabetes mellitus: a real-world pharmacovigilance study based on the FAERS database.

FAERSを用い、薬剤性妊娠糖尿病のリスク因子を解析。

対象DB：FAERS

13. Divergent neuropsychiatric and systemic toxicity profiles of abemaciclib and palbociclib: a triangulation study integrating pharmacovigilance, genetic epidemiology, and multi-omics profiling.

AbemaciclibとPalbociclibの神経精神・全身毒性の比較解析。

対象DB：FAERS

14. Mining safety signals of PD-1/PD-L1 inhibitor-related adrenal insufficiency: a study based on the FAERS database.

PD-1/PD-L1阻害薬による副腎不全のシグナルをFAERSで解析。

対象DB：FAERS

15. Posterior Reversible Encephalopathy Syndrome with Angiogenesis Inhibitors for Solid Tumours: Clues from a Disproportionality Analysis of the FDA Adverse Event Reporting System and Pharmacodynamics.

固形がんへの血管新生阻害薬によるPRESの副作用信号の探索。

対象DB：FAERS

16. Immune-Mediated upper gastrointestinal toxicities reported With immune checkpoint inhibitors: An analysis of the food and drug administration adverse event reporting system (FAERS).

免疫チェックポイント阻害薬による上部消化管毒性の解析。

対象DB：FAERS

17. Five year of post-marketing safety of teprotumumab: A disproportionality analysis of the FDA adverse event reporting system.

Teprotumumabの5年間の市販後安全性をFAERSで不均衡解析。

対象DB：FAERS

18. A retrospective pharmacovigilance analysis based on the FAERS database reveals sex-associated differences in toxicities of CAR T-cell therapy.

FAERS解析により、薬剤性副作用における性差を後方視的に特定。

対象DB：FAERS

19. Comparative Analysis of Potential Side Effects of Targeted Oral Hypoglycemic Agents Using Spontaneous Adverse Event Reports and Social Media Data.

各種経口糖尿病薬の潜在的副作用を副作用報告DBを用いて比較。

対象DB：FAERS,KAERS

20. Posterior Reversible Encephalopathy Syndrome (PRES) Associated With Lenvatinib: A Disproportionality Analysis.

レンバチニブに関連するPRESの副作用シグナルを不均衡解析。

対象DB：FAERS

21. Kidney adverse events associated with calcineurin inhibitors: a real-world study based on the FAERS database and network pharmacology.

カルシニューリン阻害薬による腎副作用をFAERSデータで解析。

対象DB：FAERS

22. Early Evaluation of the Food and Drug Administration (FDA) Adverse Event Monitoring System (AEMS): An Analysis of Over 32 Million Pharmacovigilance Reports.

FDAの副作用監視システム（AEMS）の初期評価に関する研究。

対象DB：FAERS

23. Adverse event of ACE inhibitors: A descriptive analysis of FAERS data.

ACE阻害薬の副作用に関するFAERSデータの記述的解析。

対象DB：FAERS

24. Drug- and patient-specific neurological risk profiles of alpha1-adrenergic blockers: evidence from FAERS and external validation in JADER.

α1遮断薬による神経学的リスクプロファイルをFAERSで解析。

対象DB：FAERS,JADER

25. The Cardiovascular Safety of Antiparkinsonian Drugs-Analysis of Signals in the FDA Adverse Event Report System Database.

抗パーキンソン薬の心血管安全性をFAERSシグナルで解析。

対象DB：FAERS

26. Cardiovascular Risks of COVID-19 Therapeutics: Integrated Analysis of FAERS, Electronic Health Records, and Transcriptomics.

COVID-19治療薬の心血管リスクをDB統合解析で評価。

対象DB：FAERS

27. Signal Detection of Adverse Events Associated with Four Dihydropyridine Calcium Channel Blockers Based on the FAERS Database.

4種のジヒドロピリジン系カルシウム拮抗薬の副作用シグナル検出。

対象DB：FAERS

28. Identifying Sex Differences in Adverse Events Reported on Opioid Drugs in the FDA's Adverse Event Reporting System (FAERS).

FAERS報告におけるオピオイド関連副作用の性差を特定。

対象DB：FAERS

29. Antibiotic-associated encephalopathy: A retrospective pharmacovigilance study based on 21 years of data from the US FDA Adverse Event Reporting System.

21年間のデータを用いた抗菌薬関連脳症の後方視的薬物監視。

対象DB：FAERS

30. Safety evaluation of finerenone and identification of factors contributing to nephrotoxicity: re-analysis using FDA adverse event reporting system data.

フィネレノンの安全性評価と腎毒性寄与因子の再解析。

対象DB：FAERS

31. The Real-World Endocrine Toxicity Profile of ICIs, VEGFR-TKIs, and Their Combination: Analysis of the FDA Adverse Event Reporting System (FAERS) Database.

ICI、VEGFR-TKIおよび併用療法の内分泌毒性を解析。

対象DB：FAERS

32. Post-market safety profile and suicide risk signals of vortioxetine: a real-world pharmacovigilance study.

ヴォルティオキセチンの市販後安全性と自殺リスクのシグナル。

対象DB：FAERS

33. Pemphigoid associated with quinolone antibiotics: a real-world pharmacovigilance study of the FDA adverse event reporting system and literature-based evidence.

キノロン系抗菌薬に関連する類天疱瘡のリアルワールド解析。

対象DB：FAERS

34. Adverse events profiles of pemetrexed: a Food and Drug Administration Adverse Event Reporting System.

ペメトレキセドの副作用プロファイルをFAERSデータに基づき解析。

対象DB：FAERS

35. Pharmacovigilance study of spinal epidural hematoma reports associated with direct oral anticoagulants and warfarin.

DOACに関連する脊髄硬膜外血腫報告の薬物監視研究。

対象DB：FAERS

36. Association between immune-mediated cystitis and PD-1, PD-L1, CTLA-4, and LAG-3 immune checkpoint inhibitors: A pharmacovigilance study from the FAERS database.

免疫介在性膀胱炎と各種免疫チェックポイント阻害薬の関連。

対象DB：FAERS

37. Spectrum and prognosis of CAR-T-related endocrine toxicity: glucose/calcium dysregulation, pituitary axis disorders, and overlap with CRS.

CAR-T関連内分泌毒性（糖・カルシウム代謝異常等）の解析。

対象DB：FAERS

38. Post-marketing safety evaluation of paroxetine: a real-world pharmacovigilance analysis based on the FDA adverse event reporting system.

パロキセチンの市販後安全性をFAERSデータを用いて解析。

対象DB：FAERS,KAERS

39. Exploring Risk Drugs and Mechanisms in Dystonia: Insights from Pharmacovigilance and Proteogenomics.

ジストニアのリスク薬剤と機序を薬物監視とオミクスで解析。

対象DB：FAERS

40. Association Between Dipeptidyl Peptidase-4 Inhibitor Use and Acute Kidney Injury in Patients With Diabetes Mellitus: A Disproportionality Analysis Based on the FAERS.

糖尿病患者でのDPP-4阻害薬使用と急性腎障害リスクの関連。

対象DB：FAERS

41. Post-marketing safety surveillance of EGFR-targeted agents and disseminated intravascular coagulation risk: a disproportionality analysis based on the FDA Adverse Event Reporting System.

EGFR標的薬と播種性血管内凝固症候群（DIC）の安全性監視。

対象DB：FAERS

42. Pharmacovigilance analysis and real-world adverse event profile (safety signals and product-related issues) of potassium citrate: a US FDA adverse event reporting system (FAERS) based analysis.

リアルワールドでの副作用プロファイル（製品関連等）の解析。

対象DB：FAERS

43. Interstitial lung disease associated with novel anticancer agents in non-small cell lung cancer: a pharmacovigilance analysis using the FAERS database.

非小細胞肺がんへの新規抗がん剤による間質性肺疾患の解析。

対象DB：FAERS

44. Taxane-induced macular oedema: disproportionality and timing analyses using FAERS and JADER.

タキサン系誘発性黄斑浮腫の不均衡・発現時期解析（FAERS等）。

対象DB：FAERS,JADER

45. Adverse Events Associated with Growth Hormone Therapy: A Pharmacovigilance Study.

成長ホルモン療法に関連する副作用の薬物監視研究。

対象DB：FAERS

46. Pharmacovigilance insights into drug-induced hypercalcemia: evidence from the U.S. FDA Adverse Event Reporting System (FAERS) database.

薬剤性高カルシウム血症の薬物監視。FAERSデータによる証拠。

対象DB：FAERS

47. Cutaneous adverse reactions associated with enfortumab vedotin: a pharmacovigilance study based on the FDA adverse event reporting system.

エンホルツマブ ベドチンによる皮膚副作用の不均衡解析。

対象DB：FAERS

48. Respiratory adverse events associated with PD-1/PD-L1 inhibitors: an analysis based on the FDA adverse event reporting system.

PD-1/PD-L1阻害薬に関連する呼吸器副作用のFAERS解析。

対象DB：FAERS

49. A multidimensional investigation of myelosuppression associated with sintilimab: integrating pharmacovigilance signal mining with real-world clinical evidence.

シンチリマブによる骨髄抑制の多角的調査。薬物監視と機序。

対象DB：FAERS

50. Spectrum and signals of medication-associated cognitive disorder: a comprehensive disproportionality analysis with cross-database validation.

薬剤関連の認知障害のスペクトラムとシグナルを包括解析。

対象DB：FAERS,JADER

51. Potential impact of nicorandil on the pharmacodynamics of anti-angiogenic agents.

ニコランジルが抗血管新生薬の薬力学に与える潜在的影響。

対象DB：FAERS

52. Reported drug spectrum and disproportionality signals for malignant neoplasm progression in FAERS: a real-world pharmacovigilance study.

FAERSにおける悪性腫瘍進行の報告薬剤スペクトラムとシグナル。

対象DB：JADER

53. [Trends in Spontaneous Adverse Event Reports Following the Expansion of Pembrolizumab Indications in Japan].

日本のペムブロリズマブ適応拡大に伴う副作用報告の動向。

対象DB：JADER,NDB

54. Drug-drug interaction signals between carbonic anhydrase inhibitors and vitamin D preparations in urinary tract stones: disproportionality analysis evaluation from Japanese spontaneous reports of adverse events.

尿路結石患者での炭酸脱水素酵素阻害薬とビタミンDの相互作用。

対象DB：JADER

55. Serious Adverse Drug Reactions Associated with Off-Label and Unlicensed Drug Use in Children: A 14-Year Analysis of VigiBase Reports from Serbia.

小児における適応外・未承認薬使用に伴う重篤副作用（14年分）。

対象DB：VigiBase

56. Pharmacovigilance of paracetamol-induced Stevens-Johnson Syndrome and toxic epidermal necrolysis in the Indian population.

ニュージーランドにおけるアセトアミノフェン誘発性SJS/TEN。

対象DB：VigiBase

57. Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase.

2型経口生ポリオワクチンの安全性を副作用報告データで評価。

対象DB：VigiBase

58. Real-world identification of high-risk medications for drug-induced osteoporosis: a multi-method pharmacovigilance study based on FAERS with WHO Vigibase validation.

薬剤性骨粗鬆症の高リスク薬を特定する複数手法の薬物監視。

対象DB：VigiBase

59. The Role of Electronic Medical Record Systems and Pharmacovigilance Databases in the Surveillance of Antimicrobial Use and Resistance in Low- and Middle-Income Countries: Protocol for a Multistudy Project.

電子カルテと副作用DBを用いた安全性監視における役割の検討。

対象DB：VigiBase

60. Critical care access and outcomes in residents of inpatient-care catchment areas with and without ICUs: a nationwide cohort study in Japan.

ICUのない集客圏の住民における重症病床へのアクセスと転帰。

対象DB：DPC

61. Impact of Rehabilitation on Time to Home Discharge after Hip Fracture Surgery: A Retrospective Observational Study Using the Japanese Nationwide Database of Diagnosis Procedure Combination.

股関節骨折手術後のリハビリが自宅退院までの期間に与える影響。

対象DB：DPC

62. Protective effect of bevacizumab against interstitial lung disease in non-squamous non-small-cell lung cancer: a nationwide target trial emulation study.

非扁平非小細胞肺がん患者でのベバシズマブの肺障害保護効果。

対象DB：DPC

63. Cemented total hip arthroplasty reduces early complications: a Japanese nationwide propensity-matched study.

セメント使用の全人工股関節置換術による早期合併症の減少効果。

対象DB：DPC

64. Impact of navigation assistance on perioperative outcomes in UKA: A nationwide propensity score-matched cohort study.

単顆型人工膝関節置換術（UKA）でのナビ支援の周術期への影響。

対象DB：DPC

65. Factors associated with central venous port implantation during breast cancer perioperative chemotherapy: a Japanese database study.

乳がん周術期化学療法中の中心静脈ポート留置に関連する因子。

対象DB：DPC

66. Associations between the number of benzodiazepine receptor agonists prescriptions and social determinants of health, including social capital: an ecological study.

ベンゾジアゼピン受容体作動薬の処方数と社会的決定因子の関連。

対象DB：NDB

67. Nationwide trends and regional variation in intravitreal injections and anti-VEGF agent use in Japan from 2017 to 2022: An analysis of the NDB Open Data.

日本における硝子体内注射と抗VEGF薬使用の全国動向と地域差。

対象DB：NDB

68. Real-world effectiveness of mono- and combination therapies of mood stabilisers and antipsychotics in bipolar disorder: nationwide, within-individual study of 315 046 patients.

日本の双極性障害患者での気分安定薬と抗精神病薬の有効性。

対象DB：NDB

69. Impact of Cardiovascular-Kidney-Metabolic Syndrome on Cancer Development: Insights From a Nationwide Database Study.

心血管・腎・代謝症候群ががん発症に与える影響の全国調査。

対象DB：DeSC,NDB

70. Real-world patient characteristics and clinical outcomes in patients with myelofibrosis in Japan.

日本の骨髄線維症患者におけるリアルワールドの特性と予後。

対象DB：MDV

71. Effect of sodium-glucose cotransporter 2 inhibitors on heart failure readmission in older patients with diabetes: A Japanese claims-based cohort study.

心不全合併糖尿病高齢者でのSGLT2阻害薬による再入院抑制効果。

対象DB：MDV

72. Characterizing Infectious Disease Mortality in Severe Mental Illness: A Retrospective Matched Cohort Study.

重症精神疾患患者における感染症死亡の特徴。後方視的比較。

対象DB：CPRD

73. Combined Oral Contraceptives and Stroke Risk in Individuals With Migraine With Aura.

前兆のある片頭痛患者における経口避妊薬と脳卒中リスク。

対象DB：CPRD

74. Incidence of diabetes mellitus following hospitalisation with influenza: a population-based cohort study in England.

インフルエンザ入院後の糖尿病発症率。住民ベースのコホート。

対象DB：CPRD

75. Development and validation of clinical prediction models for personalized renal function monitoring in people with heart failure in primary care: the RENAL-HF study protocol.

個別化された腎機能モニタリングのための予測モデルの開発。

対象DB：CPRD

76. Comparative safety of direct oral anticoagulants and low-molecular-weight heparin in patients with venous thromboembolism and cancer in Europe.

VTE合併がん患者におけるDOACと低分子ヘパリンの安全性比較。

対象DB：CPRD

77. Characteristics associated with regular attendance and quality of asthma annual reviews in adults with asthma in England.

成人喘息患者における定期受診と年次レビューの質に関連する因子。

対象DB：CPRD

78. Fragility fracture, atypical femoral fracture, and osteonecrosis of jaw after bisphosphonate prescription for three and five years, based on primary and secondary care data in England: nested case-control and cohort studies.

ビスホスホネート処方後の脆弱性骨折・非定型骨折・顎骨壊死。

対象DB：CPRD

79. Cyclin-dependent kinase inhibitors and kidney injury: Analysis of the French pharmacovigilance database.

CDK阻害薬と腎障害の関連。フランスの副作用DBを用いた解析。

対象DB：FPVD

80. Acquired Haemophilia A and COVID-19 mRNA Vaccine Tozinameran: Analysis of Cases Registered in the French PharmacoVigilance Database.

フランスの副作用DBを用いた mRNAワクチン後の獲得性血友病A。

対象DB：FPVD

81. Adherence and Persistence Among Individuals Living With Type 2 Diabetes and Using a Free Combination of Basal Insulin and an Injectable Glucagon-Like Peptide-1 Receptor Agonist Versus a Fixed-Ratio Combination Therapy: A Japanese Database Study.

2型糖尿病患者における配合剤と自由併用での継続率と遵守率。

対象DB：DeSC

82. Timing of Remdesivir Initiation and Clinical Outcomes in Hospitalized Patients with COVID-19 Who Are at High Risk of Disease Progression in Japan: A Health Insurance Claims Database Study.

日本のCOVID-19高リスク入院患者でのレムデシビル投与時期。

対象DB：DeSC